Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  O. Blau.  DNMT3A mutations in acute myeloid leukemia , 2016 .

[3]  A. August,et al.  The signaling symphony: T cell receptor tunes cytokine‐mediated T cell differentiation , 2015, Journal of leukocyte biology.

[4]  Xiaoyan Jiang,et al.  Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma. , 2015, Blood.

[5]  S. Lade,et al.  Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. , 2015, Blood.

[6]  S. Aerts,et al.  JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. , 2014, Blood.

[7]  J. Hess,et al.  C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis , 2014, Proceedings of the National Academy of Sciences.

[8]  S. Mustjoki,et al.  Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing , 2014, Experimental dermatology.

[9]  Qiang Feng,et al.  Identification of genomic alterations in oesophageal squamous cell cancer , 2014, Nature.

[10]  L. Ringrose,et al.  What are memories made of? How Polycomb and Trithorax proteins mediate epigenetic memory , 2014, Nature Reviews Molecular Cell Biology.

[11]  Heather L. Mulder,et al.  The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes , 2014, Nature Communications.

[12]  I. Varela,et al.  PLCG1 mutations in cutaneous T-cell lymphomas. , 2014, Blood.

[13]  Tian-Li Wang,et al.  The emerging roles of ARID1A in tumor suppression , 2014, Cancer biology & therapy.

[14]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[15]  A. Facchiano,et al.  Comprehensive analysis of PTEN status in Sezary syndrome. , 2013, Blood.

[16]  Ali Bashashati,et al.  Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling , 2013, The Journal of pathology.

[17]  Angela G. Fleischman,et al.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. , 2013, Cancer discovery.

[18]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[19]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[20]  Anthony R Green,et al.  Janus kinase deregulation in leukemia and lymphoma. , 2012, Immunity.

[21]  G. Getz,et al.  Characterization of the DNA copy-number genome in the blood of cutaneous T-cell lymphoma patients. , 2012, The Journal of investigative dermatology.

[22]  H. Friess,et al.  Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer , 2011, Gut.

[23]  P. Porcu,et al.  Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome) , 2011, British journal of haematology.

[24]  Michael N. Edmonson,et al.  Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[25]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[26]  C. Klemke,et al.  Genomic loss of the putative tumor suppressor gene E2A in human lymphoma , 2011, The Journal of experimental medicine.

[27]  J. Zucman‐Rossi,et al.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas , 2011, The Journal of experimental medicine.

[28]  C. Roberts,et al.  SWI/SNF nucleosome remodellers and cancer , 2011, Nature Reviews Cancer.

[29]  G. Przybylski,et al.  Genetic alterations in Sezary syndrome , 2011, Leukemia & lymphoma.

[30]  Kenneth H. Buetow,et al.  CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.

[31]  C. Klemke,et al.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. , 2011, Blood.

[32]  Bertil Johansson,et al.  Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia , 2010, Proceedings of the National Academy of Sciences.

[33]  J. Scarisbrick,et al.  Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  I. Weissman,et al.  T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell , 2010, Proceedings of the National Academy of Sciences.

[35]  H. Nakauchi,et al.  Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-β1-mediated growth suppression in adult T-cell leukemia/lymphoma , 2010, Oncogene.

[36]  I. Ial,et al.  Nature Communications , 2010, Nature Cell Biology.

[37]  P. Fadda,et al.  Identification of key regions and genes important in the pathogenesis of sezary syndrome by combining genomic and expression microarrays. , 2009, Cancer research.

[38]  R. Levine,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[39]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[40]  M. F. Shannon,et al.  The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. , 2009, International immunology.

[41]  X. Mao,et al.  Functional copy number changes in Sézary syndrome: toward an integrated molecular cytogenetic map III. , 2008, Cancer genetics and cytogenetics.

[42]  J. Yokota,et al.  Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. , 2008, Blood.

[43]  Y. Chung,et al.  Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers , 2008, Clinical Cancer Research.

[44]  D. Rawlings,et al.  The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes , 2006, Nature Reviews Immunology.

[45]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[46]  P. Dallas,et al.  Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. , 2004, The Biochemical journal.

[47]  S. Whittaker,et al.  Molecular cytogenetic characterization of Sézary syndrome , 2003, Genes, chromosomes & cancer.

[48]  S. Orkin,et al.  Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. , 2002, Cancer cell.

[49]  J. Scarisbrick,et al.  Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. , 2001, The Journal of investigative dermatology.

[50]  Unnur Thorsteinsdottir,et al.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b , 1998, The EMBO journal.

[51]  T. Hudson,et al.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome , 1998, Nature Genetics.

[52]  G. Wogan,et al.  The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.